No products in the cart.
Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
Tag: BRAF inhibitor
Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia
1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc ...
#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF and MEK inhibitor combination therapy shows efficacy for advanced melanoma in Japanese patients
Click to read the study in the European Journal of Cancer.
#VisualAbstract: BRAF/MEK inhibitor therapy may be associated with risk of uveitis in patients with advanced melanoma
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.
#VisualAbstract: Low plasma ctDNA may be predictive of better survival outcomes in patients with melanoma receiving first-line immune checkpoint inhibitors
Click to read the study in Clinical Cancer Research
#VisualAbstract: Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.